Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00191867
NCT00191867
Completed
Phase 2

Assessment of Dose Response of LY333334 in Japanese Postmenopausal Women With Osteoporosis

Eli Lilly and Company1 site in 1 country160 target enrollmentFebruary 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOsteoporosis
DrugsTeriparatide

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Osteoporosis
Sponsor
Eli Lilly and Company
Enrollment
160
Locations
1
Primary Endpoint
To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.

Registry
clinicaltrials.gov
Start Date
February 2005
End Date
March 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Japanese women with primary osteoporosis
  • •Postmenopausal women aged at least 55 years
  • •Patients with a high risk for fracture

Exclusion Criteria

  • •History of metabolic bone disorders other than osteoporosis
  • •History of any secondary causes of osteoporosis
  • •History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated
  • •Severe or chronically disabling conditions other than osteoporosis

Outcomes

Primary Outcomes

To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint

Secondary Outcomes

  • To evaluate the safety of LY333334

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 DiabetesType 2 Diabetes Mellitus
NCT03322631Eli Lilly and Company48
Completed
Not Applicable
Assessment of Response to Thienopyridine in Japanese Population (ART-JP)coronary artery disease (CAD)
JPRN-UMIN000006336Keio University, School of Medicine, Research Park 5S9300
Completed
Phase 1
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2
NCT04823208Eli Lilly and Company64
Completed
Phase 1
A Study of LY3039478 in Japanese Participants With Advanced Solid TumorsAdvanced Solid Tumor
NCT02836600Eli Lilly and Company11
Completed
Phase 4
COMACHIHER2- positive inoperable or recurrent breast cancer
JPRN-jRCT1080222272Chugai Pharmaceutical Co., Ltd.132